Mette Kenfelt's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (3)
Objectives
To assess the benefits and harms of aluminium adjuvants versus placebo or no intervention in randomised clinical trials in relation to human vaccine development.
Design
Systematic review with meta-analysis and trial sequential analysis assessing the certainty of evidence with Grading of Recommendations Assessment, Development and Evalua...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of aluminium adjuvants used in a vaccine or an excipient versus the same vaccine or excipient, but having a different type of aluminium adjuvant formulation, or a different concentration, or with a different particle size.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of aluminium adjuvants used in vaccines versus placebo or no intervention, taking into consideration the type of the vaccine, and the type, size and concentration of aluminium adjuvant. © 2017 The Cochrane Collaboration. Publishe...
Citations
... Achieving satisfactory immunological defense against HBV infection recently requires multiple immunization programs (MIP) with recombinant HBV surface antigen (rHBsAg) adjuvanted with Alums [8]. Generally, the vaccines shot are administered in prime and boost doses within 6 months [9]. Though, with the MIP alternatives, some success in combating HBV infection has been achieved. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/363337960443904-1463637928183_Q64/Janus-Jakobsen-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/886632697827328-1588401116348_Q64/Sesilje-Petersen.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272779480137736-1442047104505_Q64/Christian-Gluud.jpg)
... Adjuvants are chemical or biological compounds that stimulate the immune system against the administered antigen, thus, increasing the effectiveness of the vaccine [75]. Among the most common adjuvants, aluminum (Alum)-based compounds, such as amorphous Alum hydroxy-phosphate sulphate (AAHS), Alum hydroxide, Alum phosphate, and potassium Alum sulphate, are the most used in conventional human vaccines [76]. Synthetic oligodeoxynucleotides (ODNs) are also adjuvants; they contain unmethylated CpG motifs and can trigger cells expressing TLR9 inducing a Th1 response and proinflammatory cytokines. ...
